A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-94.

Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-61.

Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368-76.

El-galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041-6.

Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26(8):1163-72.

Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010;21(7):1486-91.

Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92(10):3562-8.

Fanin R, Silvestri F, Geromin A, et al. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index. Bone Marrow Transplant. 1998;21(3):263-71.

Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol. 1997;8 Suppl 1:49-52.

Hermans J, Krol AD, Van groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995;86(4):1460-3.

Dr. Laurie H. Sehn

International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

aarbor_stage

ecog

serum

nodal

Predicts overall and progression-free survival in DLBCL based on risk factors.

IPI and R-IPI

Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.

Randall Pierce, MD

The Revised International Prognostic Index (R-IPI) for Diffuse Large B-cell Lymphoma predicts overall and progression free survival based on risk factors.

FLIPI for Follicular Lymphoma

MIPI

GELF Criteria for Follicular Lymphoma

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function